HOME >> BIOLOGY >> NEWS
Breast cancer is multi-step, multi-cell type process

COLUMBUS, Ohio -Researchers at The Ohio State University Comprehensive Cancer Center are offering one of the first models of breast cancer as a multi-step process which involves more than one cell type, thanks in part to new laser-microdissection technology which enables them to take apart tumors one cell at a time.

Scientists know cancer develops over a period of years through a series of genetic changes or mutations. Scientists have also long accepted that these genetic mutations occur in a single cell type for any given cancer. But the sequence of events-which "hits" happen first, and which specific cells are involved-has not been clearly documented until now.

Writing in the September 1 issue of Human Molecular Genetics, a research team, led by Dr. Charis Eng, director of the Clinical Cancer Genetics Program at Ohio State, says it has uncovered evidence suggesting that genetic changes leading to breast cancer occur first in the epithelium of breast tissue, and then are followed by corresponding alterations in the surrounding structures, or stroma.

"This is almost paradigm-breaking," says Eng. "In breast cancer, the alterations that lead to malignancy are thought to occur only in the epithelial cells of the breast. We have shown for the first time that genetic mutations can occur with some frequency in the stromal cells, too."

Utilizing laser capture microdissection, (LCM) investigators examined the tissue of 41 invasive breast cancers. In LCM technology, a laser beam only 7.5 microns in width - roughly one-tenth the size of a human hair -- acts as a "knife"- enabling researchers to isolate cancerous cells from normal cells, and to separate epithelial cells from stromal cells.

"Before LCM, the study of cancer genetics entailed grinding up a lump of tumor comprising a mixture of cells and examining the 'mixed bag' of cells for gene alterations," says Eng. "We really couldn't attribute genetic changes to any one cell type. LCM allo
'"/>

Contact: Michelle Gailiun
gailiun.1@osu.edu
614-293-3737
Ohio State University Medical Center
1-Sep-2001


Page: 1 2

Related biology news :

1. Breast cancer patients failed by treatment with taxol and taxotere respond to abraxane
2. Breastfeeding decreases infant mortality
3. Breast cancer study suggests role for tissue in carcinogenesis
4. Breast self examination increases womens concerns but has no effect on mortality
5. Breast cancer follow-ups no longer guess-work thanks to new physics research
6. Final media advisory for the 4th European Breast Cancer Conference (EBCC-4)
7. The 4th European Breast Cancer Conference (EBCC4)
8. Breast cancer susceptibility genes play role in DNA repair
9. Breast cancer can be reversed in laboratory mice, scientists report
10. NIH funds Breast Cancer and the Environmental Research Center at Fox Chase Cancer Center
11. Breast fluid a better option for detecting cancer

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Breast cancer multi step multi cell type process

(Date:10/16/2014)... Cancer constantly wages war on the human body. ... a stalemate. In pancreatic cancer, this stalemate—known as ... becoming aggressively malignant, a phenomena that is poorly ... in the laboratory of Salvatore Torquato, a Professor ... the conditions surrounding tumor dormancy and the switch ...
(Date:10/16/2014)... cultivated efficiently, they are anything but sustainable: environmental ... cultivation is becoming increasingly evident. Despite their disadvantages, ... are regarded as the sole possibility of achieving ... finds Bernhard Schmid, an ecology professor at the ... of agriculture and forestry. After all, a new ...
(Date:10/15/2014)... , Oct. 15, 2014 Sandata Technologies, ... home and community-based care, today announced it released ... Sandata,s Santrax® Electronic Visit Verification™ Solution (EVV™)  for ... a home health company founded in 1996 and ... . The study details the ...
Breaking Biology News(10 mins):Modeling tumor dormancy 2Plant communities produce greater yield than monocultures 2Plant communities produce greater yield than monocultures 3Sandata Announces Case Study with Quality Care Services, Inc. 2
(Date:10/22/2014)... , Oct. 22, 2014 Nuvilex, Inc. ... approximately 400 million people worldwide are living with diabetes, ... people by 2030.  The global market for diabetes treatments ... approximately 330,000 people worldwide died from pancreatic cancer.  Pancreatic ... due to cancer in the United States ...
(Date:10/20/2014)... The report “Pharmacy Automation Systems Market ... Labeling Systems, Table-top Counters) by End-user (Inpatient Pharmacy ... Trends to 2019” analyzes and studies the major ... Europe, Asia-Pacific, and the Rest of the World ... figures spread through 300 pages and in-depth TOC ...
(Date:10/20/2014)... PARK, Calif. , Oct. 20, 2014 /PRNewswire/ ... today that the Company has signed a Notice ... of Regenerative Medicine (CIRM), effective October 1, 2014.  ... Clinical Development payments and the release of additional ... million CIRM grant award for clinical development of ...
(Date:10/20/2014)... Md. , Oct. 20, 2014  GenVec, Inc. (NASDAQ: ... Zola P. Horovitz , Ph.D., from its board of directors ... board in August 2003, and served as its chairman from ... served on the Nominating and Corporate Governance and Audit Committees ... for more than a decade of dedicated service to GenVec, ...
Breaking Biology Technology:Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4Zola P. Horovitz To Retire From GenVec Board 2
Cached News: